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Foreword
Platelet aggregation is a major factor in acute ischaemic
syndromes (unstable angina and myocardial infarction)
and excessive platelet aggregation can complicate coro-
nary interventions. In clinical practice, platelet aggregation
is usually initiated by spontaneous rupture of a coronary
plaque, or by iatrogenic rupture (dissection) during coro-
nary intervention. Current treatment of unstable angina
and myocardial infarction includes aspirin, a weak plate-
let aggregation inhibitor, and heparin as anticoagulant.
Similarly aspirin and heparin are used routinely to avoid
thrombotic complications during coronary intervention. In
spite of such combination therapy, platelet aggregation
remains a major clinical problem in subgroups of patients
with unstable angina and during coronary intervention.
Recently several new approaches have been taken to
avoid platelet aggregation, including development of
specific platelet GP Ilb-IIIa receptor blockers and the
development of specific thrombin inhibitors. During a sym-
posium at the European Heart House on 16-18 February
1995 these developments were reviewed. This supplement
contains the papers discussed at the symposium focusing on:
the pathophysiology of plaque disruption, platelet aggre-
gation; developments in antiplatelet and antithrombotic
therapy; identification of patient subgroups at low risk and
high risk for thrombotic complications during coronary
interventions; current experience with c7E3 (ReoPro), a
platelet GP Ilb-IIIa receptor blocker which has recently
been introduced in clinical practice; an overview of other
antiplatelet agents and specific antithrombins; clinical ap-
plication of platelet GP Ilb-IIIa receptor blockers and (in
the future) specific antithrombins including a discussion of
bleeding risks and cost efficacy of such therapy; finally,
guidelines for prevention and management of thrombotic
complications during coronary interventions are discussed.
The rapid developments and challenges in this field are
best illustrated by two trials which have been presented and
published recently. The EPIC trial, as summarized by Califf
Table 1 Comparison of patients in the EPIC study (c7E3 for high
risk PTCA procedures) with the HELVETICA study (hirudin for
unstable angina). In both studies, three patient groups were com-
pared. This table contains data from patients in the control group
(placebo and heparin in EPIC and HELVETICA, respectively)
and patients with the highest dose ofc7E3 (bolus + infusion) and
hirudin (infusion + subcutaneous administration). Patient char-
acteristics among the two studies were similar
EPIC HELVETICA
Patients
Age (years)
Male (%)
Previous MI (%)
Previous PTCA (%)
Previous CABG (%)
Acute unstable angina (%)
Placebo
696
61
72
57
23
15
43
c7E3
708
Heparin Hirudin
382 378
58
79
40
17
3
29
in this supplement, demonstrated that administration of the
c7E3 antibody reduced thrombotic complications during
and after coronary angioplasty. A significant reduction of
events was achieved early after the intervention, at 30 days,
and at 6 months follow-up. In fact, further separation of the
event-free survival curves up to 6 months suggested that
short-term administration (12 h) of c7E3 might have a
long-term effect and might reduce the rate of restenosis.
Unfortunately, angiography was not repeated at 6 months
in the EPIC study. Further studies are ongoing to assess the
mechanism of this observation'1"31.
The HELVETICA study, with recombinant hirudin,
enrolled patients with characteristics similar to those in
EPIC (Table 1). Inhibition of anticoagulation and platelet
aggregation by the specific antithrombin yielded a similar
clinical effect at 30 days as observed with c7E3 in EPIC
(Table 2). However, at 6 months follow-up, no difference
was found in event rates in patients receiving hirudin or
heparin'4-51.
The similarity of the early reduction of events by c7E3
and hirudin, and the apparent difference in late effect is
intriguing. Several possibilities to explain this discrepancy
should be considered. First, both studies confirm that inhi-
bition of platelet aggregation (and anticoagulation) offers
a major benefit with reduction of thrombotic events in
patients undergoing coronary intervention, without exces-
sive bleeding risk. Second, it is possible that the difference
in long-term efficacy of both compounds is a chance finding.
In fact, the number of events during follow-up is small in
both studies, and the confidence intervals for the late effects
are wide. Third, several mechanisms have been proposed
which might explain a long-term effect of c7E3, including
inhibition of vitronectin receptor mediated intimal hyper-
Table 2 Comparison of outcome at 30 days and 6 months in the
EPIC and HELVETICA studies (see Table 1). Note a remarkable
similarity in reduction of events during the first 30 days among the
two studies. (HELVETICA data at 30 days kindly provided by the
investigators). At 6 months follow-up, a further reduction in events
by c7E3 in EPIC was reported, while event rates in the two treatment
groups in HELVETICA were similar. Several explanations for this
contrast between early and late effects of c7E3 and hirudin are
discussed
EPIC HELVETICA
MI = myocardial infarction; PTCA = percutaneous transluminal
coronary angioplasty; CABG = coronary artery bypass surgery.
Patients
30 days
Death (%)
Infarction (%)
PTCA(%)
CABG (%)
Any event (%)
6 months
Death (%)
Infarction (%)
PTCA (%)
CABG(%)
Any event (%)
Placebo
6%
1.7
8.6
4.5
3.6
12.8
3.4
10.5
20.9
10.9
35.1
c7E3
708
1.7
5.2
0.8
2.4
83
3.1
6.9
14.4
9.4
27.0
Heparin
382
0.8
4.7
4.5
3.1
12.8
1.0
4.5
19.6
7.6
32.7
Hirudin
378
1.1
3.4
2.1
2.4
7.7
2.9
4.0
193
5.8
32.0
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